Penn State College of Medicine, Beat Childhood Cancer Research Consortium and Four Diamonds launch clinical trial that aims to combat solid tumors
In a step toward fighting solid tumors in children and young adults, Penn State College of Medicine, the Beat Childhood Cancer Research Consortium and Four Diamonds, along with Senhwa Biosciences, Inc. are launching a pioneering clinical[...]
Q&A: Finding novel therapies for childhood cancer
Since the first time she treated a child with neuroblastoma, Giselle Saulnier Sholler wanted to do the impossible for her patients. Neuroblastoma is the most common extracranial solid tumor in children with[...]
FDA approves pediatric neuroblastoma drug based on Penn State professor’s work
Giselle Saulnier Sholler, professor of pediatrics and of pharmacology, reflects on 20 years working to change cancer outcomes for children HERSHEY, Pa. — In 2003, the first year of her[...]
US WorldMeds Announces FDA Approval of IWILFIN™ (eflornithine) to Strengthen Fight Against Aggressive Childhood Cancer
LOUISVILLE, Ky.--(BUSINESS WIRE)--USWM, LLC (US WorldMeds) today announced that the U.S. Food and Drug Administration (FDA) has approved IWILFIN™ (eflornithine) 192 mg tablets, a groundbreaking oral maintenance therapy for high-risk[...]
Penn State Health recruits leading researcher to fight pediatric cancer
Cris Collingwood//August 2, 2023 An internationally known physician-scientist and her research consortium have joined Penn State Health to continue efforts to eradicate pediatric cancer. Penn State Health and Penn State College of Medicine[...]
The Power of Will
Will Lacey was just a baby when doctors diagnosed a rare form of cancer and told his family there was only one end. Nobody then could imagine the journey ahead,[...]
Michigan Child Trials Target Genetic Roots of Cancers
Thank you Detroit News for featuring a story about the work we are doing. It wouldn’t be possible without the support of Dell, TGen Foundation and our generous community. Together,[...]
$1,100,000 for Beat Childhood Cancer Research!
On December 24, 2014 the Grand Rapids community surpassed the Million Dollar Challenge by raising $1,100,000 for NMTRC research! This donation was then matched by a generous Beat NB donor[...]
Endowment Gift Establishes Haworth Family Pediatric Oncology Innovative Therapeutics Clinic at Helen Devos Children’s Hospital
Children fighting cancer have new hope thanks to an endowment gift from Dick and Ethie Haworth to the Helen DeVos Children’s Hospital Foundation. Their major gift establishes the Haworth Family[...]
Research: Beat Childhood Cancer
The Beat Childhood Cancer Research Consortium is a group of 54+ universities and children's hospitals
Last week was the 2025 Association of Pediatric Hematology/Oncology Nurses (APHON) Conference in Providence, Rhoad Island. The conference offers nurses access to cutting-edge sessions, keynote speakers, and networking opportunities.
One of our BCC nurses, Suzanne Treadway, from Site 22, Penn State Health Children's Hospital, presented on behalf of BCC our poster on the safety comparisons of different dose levels of DFMO. Suzanne is a remarkable patient advocate and exemplifies the very best qualities of a dedicated and compassionate nurse.
When asked what she loved about APHON this year, she said "It's my first in person conference in years and I loved seeing so many old friends. It has been a thrill to hear so many stories of success with DFMO/IWILFIN."
This content isn't available right now
When this happens, it's usually because the owner only shared it with a small group of people, changed who can see it or it's been deleted.
NEW PUBLICATION ALERT!!
New publication in The Journal of Pediatric Hematology/Oncology this month titled "Naxitamab-combination Therapy for the Treatment of Patients with Refractory and/or Relapsed High-risk Neuroblastoma".
"Approved treatments for patients with refractory and/or relapsed (R/R) high-risk (HR) neuroblastoma are limited, and there is a need for new treatment combinations. In this case series, 4 patients were treated with the anti-GD2 monoclonal antibody naxitamab and granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with cyclophosphamide and topotecan between August 2021 and December 2022. This combined
chemoimmunotherapy regimen was well tolerated in these heavily pretreated patients with R/R HR neuroblastoma who had few treatment options and overall poor prognoses."
Read more at the link: www.ncbi.nlm.nih.gov/pubmed/40793753
We are excited to be hosting an Expert Panel at the Annual Advancing Precision Medicine Conference in Philadelphia, PA on October 3, 2025 titled "Transforming Pediatric Oncology: The Power of Precision Medicine"
Our panel is hand-selected to highlight innovations in pediatric oncology precision medicine including bioinformatics, proteomics, genomics, immunotherapy, and clinical implementation. We hope to facilitate a lively discussion on current practices, translational gaps, and future directions in this 50 minute session. Please join us if you are able to attend!
Attendance is completely free for the academic and non-profit community, and complimentary CME credits will be offered to all participants. Register at this link: urldefense.com/v3/__https://www.advancingprecisionmedicine.com/apm-home/apm-annual-conference-and...
This content isn't available right now
When this happens, it's usually because the owner only shared it with a small group of people, changed who can see it or it's been deleted.Dr Jacqueline Kraveka, a member of the BCC Executive Committee, the BCC018 Study Chair, and BCC PI at the Medical University of South Carolina is in Brazil this week visiting Dr. Natalia Ambar and the team at GRAACC! We are excited to bring BCC Clinical Trials to the patients in Sao Paulo later this year! The first trial that will open in Brazil will be the BCC018 trial adding anti-GD2 therapy called naxitamab to upfront high risk neuroblastoma induction therapy to improve patient responses at end of induction. We look forward to adding GRAACC and Dr. Ambar to our BCC family!
